Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.
Terns Pharmaceuticals, Inc. (NASDAQ: TERN) is a clinical-stage biopharmaceutical company advancing novel small molecule therapies for liver diseases, oncology, obesity, and hematologic disorders. This page serves as the definitive source for official company announcements, clinical trial updates, and strategic developments.
Investors and researchers will find timely updates on TERN-701 (chronic myeloid leukemia therapy), metabolic disorder candidates, and regulatory milestones. Our curated news collection includes:
• Clinical trial progress reports
• FDA submission updates
• Research partnership announcements
• Financial results disclosures
All content is sourced directly from company filings and verified press releases. Bookmark this page to monitor Terns' innovative work in molecularly-targeted therapies and capital-efficient drug development.
Terns Pharmaceuticals, a biopharmaceutical company, announces positive data from a Phase 1 study of TERN-701, a potential BCR-ABL inhibitor for CML treatment, showing no food effect on dosing. The ongoing study in healthy volunteers displayed promising results, supporting once-daily dosing with or without food. The company aims to differentiate TERN-701 from the current standard, asciminib, by offering more convenient dosing options. Phase 1 CARDINAL trial is ongoing, with interim data expected in late 2024.
FAQ
What is the current stock price of Terns Pharmaceuticals (TERN)?
What is the market cap of Terns Pharmaceuticals (TERN)?
